Jan. 20, 2011
NewsCompany News

Parkinson’s Disease: Drug Development

Domain Therapeutics and Merck Serono

Domain Therapeutics announced that an exclusive development and licensing agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, was signed to develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson's disease and other neurodegenerative diseases.

Domain Therapeutics will contribute optimized compounds that have been developed from its proprietary chemical series. Under the terms of the agreement, the company will receive EUR 2 million in upfront payment and research funding, and is eligible for up to EUR 132 million in milestones for the first two products, as well as undisclosed royalties.



Merck Serono GmbH
Alsfelder Straße 17
64289 Darmstadt, Hessen
Phone: +49 6151 6285 0
Telefax: +49 6151 6285 812

Register now!

The latest information directly via newsletter.

To prevent automated spam submissions leave this field empty.